Most Recent
Suit alleges barrister used $1.3M of his company’s funds for chambers fees
Shareholders in lending platform Marketlend can bring a derivative suit against its directors for allegedly misusing company funds, including spending $1.3 million on barrister chambers fees. 
CBA class actions win halt to costs battle pending appeal
Applicants in two dismissed class actions against the Commonwealth Bank have secured an order staying an assessment of costs in the failed cases until the outcome of an appeal.
Phoslock, KPMG to turn over info for possible shareholder class action
Water treatment company Phoslock and auditor KPMG and have agreed to produce documents for a possible shareholder class action, but a privilege fight may still be on the cards.
Failed CBA class actions want to stay fight over costs
Two failed shareholder class actions against the Commonwealth Bank of Australia want to delay paying the bank's costs until after their 62-ground appeal is heard.
ASIC’s former deputy chair Karen Chester cleared by corruption watchdog
The corruption watchdog has issued a statement in response to reports suggesting ex-ASIC official Karen Chester faced an investigation, saying the deputy chair was never the subject of a probe.
Boral class action trial paused as appeal flagged over questioning of ex-CEO
Trial in a shareholder class action against Boral has been halted amid an appeal over a decision to allow questioning of former CEO Michael Kane about an email that mentioned a confidential EY report.
Blue Sky directors may be ‘dragged back’ into shareholder class action, court told
Three former Blue Sky directors who were originally named in a shareholder class action against the collapsed fund manager might be "dragged back" into the case after its chief operating officer pointed the finger at him in his defence, a court has heard.
Class action can grill Boral boss over email reference to EY’s dismal take on US biz
Boral's former CEO Michael Kane can be questioned at trial over a reference he made in an email to findings by EY about the building material group's poor performing US windows business, despite claims that the findings were privileged.
Mesoblast reaches settlement in class action over COVID-19 treatment
Mesoblast has agreed to settle a shareholder class action centred on statements to the market about its Remestemcel-L treatment, resolving claims it misrepresented the efficacy of the therapy for COVID-19 patients.
Domino’s hit with shareholder class action
Domino’s has been stung with shareholder class action accusing the pizza giant of misleading the market about its expected performance in Japan.